Pooled prevalence rates of developing aCL, LA, and anti-β2-GPI antibodies in patients with solid tumors (n = 31 studies)
| Cancer type (no. of studies) . | No. of positive patients . | No. of total patients . | Pooled prevalence* (95% CI), % . |
|---|---|---|---|
| Anticardiolipin antibodies | |||
| GI (n = 7)19,26-30,40 | 50 | 293 | 15 (8-24) |
| Breast (n = 5)30,32,40-42 | 35 | 220 | 9 (1-23) |
| GU (n = 5)30,31,40,43,44 | 111 | 457 | 26 (10-45) |
| Lung (n = 3)24,30,40,45 | 12 | 112 | 7 (2-14) |
| Melanoma (n = 3)30,46,47 | 6 | 136 | 0 (0-7) |
| Bone/soft tissue (n = 1)40 | 0 | 14 | 0 (0-22) |
| CNS (n = 2)30,40 | 0 | 11 | 0 (0-14) |
| Unspecified solid tumor (n = 4)25,30,48-50 † | 42 | 227 | 28 (1-70) |
| Anti-β2-GPI antibodies | |||
| GU (n = 4)40,44,51,52 | 59 | 476 | 8 (2-16) |
| Breast (n = 2)40,42 | 31 | 58 | 53 (39-66) |
| Lung (n = 2)24,40,45 | 23 | 85 | 24 (14-35) |
| Bone/soft tissue (n = 1)40 | 0 | 14 | 0 (0-22) |
| Central nervous system (n = 1)40 | 0 | 9 | 0 (0-30) |
| GI (n = 3)26,33,40 | 9 | 124 | 5 (1-10) |
| Unspecified solid tumor (n = 1)25 | 0 | 142 | 0 (0-3) |
| LA | |||
| Lung (n = 2)24,45,53 | 147 | 314 | 47 (41-52) |
| Breast (n = 2)32,54 | 3 | 135 | 2 (0-5) |
| Bone/soft tissue (n = 1)23 | 4 | 5 | 80 (38-96) |
| GI (n = 1)54 | 1 | 33 | 3 (1-15) |
| Unspecified solid tumor (n = 2)25,49,50 | 22 | 181 | 6 (3-10) |
| Unspecified aPL antibodies | |||
| Breast (n = 3)34,41,59 | 43 | 201 | 21 (16-27) |
| GU (n = 4)35,51,52,55,56 | 127 | 414 | 31 (22-41) |
| GI (n = 2)34,57 | 14 | 66 | 21 (11-31) |
| Lung (n = 1)34 | 2 | 8 | 25 (7-59) |
| Head and neck (n = 1)34 | 4 | 16 | 25 (10-49) |
| Unspecified solid tumor (n = 2)25,58 | 23 | 247 | 7 (4-11) |
| Cancer type (no. of studies) . | No. of positive patients . | No. of total patients . | Pooled prevalence* (95% CI), % . |
|---|---|---|---|
| Anticardiolipin antibodies | |||
| GI (n = 7)19,26-30,40 | 50 | 293 | 15 (8-24) |
| Breast (n = 5)30,32,40-42 | 35 | 220 | 9 (1-23) |
| GU (n = 5)30,31,40,43,44 | 111 | 457 | 26 (10-45) |
| Lung (n = 3)24,30,40,45 | 12 | 112 | 7 (2-14) |
| Melanoma (n = 3)30,46,47 | 6 | 136 | 0 (0-7) |
| Bone/soft tissue (n = 1)40 | 0 | 14 | 0 (0-22) |
| CNS (n = 2)30,40 | 0 | 11 | 0 (0-14) |
| Unspecified solid tumor (n = 4)25,30,48-50 † | 42 | 227 | 28 (1-70) |
| Anti-β2-GPI antibodies | |||
| GU (n = 4)40,44,51,52 | 59 | 476 | 8 (2-16) |
| Breast (n = 2)40,42 | 31 | 58 | 53 (39-66) |
| Lung (n = 2)24,40,45 | 23 | 85 | 24 (14-35) |
| Bone/soft tissue (n = 1)40 | 0 | 14 | 0 (0-22) |
| Central nervous system (n = 1)40 | 0 | 9 | 0 (0-30) |
| GI (n = 3)26,33,40 | 9 | 124 | 5 (1-10) |
| Unspecified solid tumor (n = 1)25 | 0 | 142 | 0 (0-3) |
| LA | |||
| Lung (n = 2)24,45,53 | 147 | 314 | 47 (41-52) |
| Breast (n = 2)32,54 | 3 | 135 | 2 (0-5) |
| Bone/soft tissue (n = 1)23 | 4 | 5 | 80 (38-96) |
| GI (n = 1)54 | 1 | 33 | 3 (1-15) |
| Unspecified solid tumor (n = 2)25,49,50 | 22 | 181 | 6 (3-10) |
| Unspecified aPL antibodies | |||
| Breast (n = 3)34,41,59 | 43 | 201 | 21 (16-27) |
| GU (n = 4)35,51,52,55,56 | 127 | 414 | 31 (22-41) |
| GI (n = 2)34,57 | 14 | 66 | 21 (11-31) |
| Lung (n = 1)34 | 2 | 8 | 25 (7-59) |
| Head and neck (n = 1)34 | 4 | 16 | 25 (10-49) |
| Unspecified solid tumor (n = 2)25,58 | 23 | 247 | 7 (4-11) |